585 a French Multicentric Longitudinal Descriptive Study of Hepatocellular Carcinoma Management (The Changh Cohort): Preliminary Results

Clinical characteristics of patients with hepatocellular carcinoma in Austria – is there a need for a structured screening program?

“…It was the aim of this study to investigate changes of clinical characteristics of patients diagnosed with HCC at our department before and after the publication of the EASL guidelines in 2001. Similar to others [20][21][22][23], we observed an increasing prevalence of obesity, diabetes, and consequently NASH. Th is issue affi rms the general fi nding that NASH is an upcoming and emerging etiological factor of cirrhosis and liver cancer.…”

“…In the fi rst period chronic viral hepatitis was the major risk factor for developing HCC, alcoholic cirrhosis became the predominant etiology in period 2. Th is is in line with data from other regions in Europe like Southern Germany, Portugal, and France [20,31,32], but is diff erent from many other countries [3,33,34], where the majority of cases are still attributed to chronic HCV infection.…”

Early detection and curative treatment of hepatocellular carcinoma: A cost‐effectiveness analysis in France and in the United States

“…Patients entered the model in the “ Compensated cirrhosis ” state; upon being diagnosed with nodules or with liver cancer, they transited to “ Nonmalignant nodules ” or “ HCC ” states. Curative treatments of HCC included surgical LR, percutaneous RFA, and LT. We used the current distribution for each first‐line curative treatment in France based on cohort data: 16% of patients had access to LR, 72% RFA, and 12% LT in the gold‐standard monitoring group versus 34%, 38%, and 28%, respectively, in the real‐life monitoring group . These percentages represented actual treatments and took into account access limitations, such as organ availability.…”

“…The clinical practice guidelines endorsed by the French National Authority for Health, in line with all other guidelines from Europe, the United States, and Asia, recommend biannual ultrasound monitoring in order to detect HCC at a curable stage. Nevertheless, fewer than 20% of patients with cirrhosis are effectively enrolled in surveillance programs, and late‐stage tumor detection is frequent . 60% to 70% of patients enrolled in a surveillance program receive HCC curative treatment versus 20% for those not in the program .…”

Hepatocellular Carcinoma in a Tertiary Referral Hospital in Indonesia: Lack of Improvement of One-Year Survival Rates between 1998-1999 and 2013-2014

“…(Johnson et al, 2015) Several studies in US and Europe have demonstrated that surveillance for HCC in high-risk patients is being underutilized in clinical practice. (Davila et al, 2010;Rosa et al, 2010;Davila et al, 2011;Singal et al, 2011;Singal et al, 2012) Surveillance rate was only 18,4% and was significantly higher among patients followed in subspecialty gastroenterology clinics. (Singal et al, 2012) The difference between Japan and other countries was the government involvement in the education and preventive measures.…”